Literature DB >> 9253324

Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency.

A Juul1, K Holm, K W Kastrup, S A Pedersen, K F Michaelsen, T Scheike, S Rasmussen, J Müller, N E Skakkebaek.   

Abstract

Serum levels of total insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) reflect endogenous GH secretion in healthy children, which makes them good diagnostic markers for screening of GH deficiency (GHD) in short children, although some controversy still exists. Only a minor fraction of the total IGF-I circulates in its free form, which is believed to be the biologically active form. However, our knowledge of the clinical or physiological value of determination of free IGF-I in serum is limited at present. In adults, the diagnostic value of total IGF-I and IGFBP-3 determinations in patients suspected of GHD has only been reported in a few studies, whereas no previous reports on the diagnostic value of free IGF-I levels in adults suspected of GHD exist. Serum levels of free IGF-I were determined in 1430 healthy children, adolescents, and adults by a newly developed, commercially available immunoradiometric assay (Diagnostic Systems Laboratories) to establish valid normative data for this analysis. We studied the diagnostic value of free IGF-I in relation to total IGF-I and IGFBP-3 determinations in adults who were suspected of GHD. A GH provocative test, using oral clonidine, was performed in 108 adult patients who had previously been treated with GH in childhood. In healthy subjects, free IGF-I levels increased during childhood, with the highest mean values during puberty. After puberty, a subsequent decline in serum levels of free IGF-I was apparent. We found, unmeasurable free IGF-I values in 34 of the prepubertal children (3.3%). All individuals over 8 yr of age had measurable free IGF-I levels that amounted to approximately 1% of the total IGF-I concentrations. Free IGF-I levels were below--2 SD in 56 of 79 GHD patients (sensitivity, 71%) and above--2 SD in 24 of 29 patients with a normal GH response (specificity, 83%). Multiple linear regression analysis demonstrated that free IGF-I was significantly dependent on peak GH levels, duration of the disease, and number of other pituitary axes affected. We conclude that free IGF-I serum levels increase during childhood with a peak in puberty, whereafter free IGF-I levels return to prepubertal levels. Three percent of healthy prepubertal children had unmeasurable free IGF-I levels using this assay. We found that determination of the free IGF-I serum concentration may predict the outcome of a GH provocative test in adults suspected of GHD, but that a single determination of free IGF-I offered no significant advantage compared to determination of total IGF-I or IGFBP-3 serum levels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9253324     DOI: 10.1210/jcem.82.8.4137

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

1.  Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation.

Authors:  H Yu; J Mistry; M J Nicar; M J Khosravi; A Diamandis; J van Doorn; A Juul
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Is the measurement of free IGF-I more indicative than that of total IGF-I in the evaluation of the biological activity of the GH/IGF-I axis?

Authors:  J A Janssen; S W Lamberts
Journal:  J Endocrinol Invest       Date:  1999-04       Impact factor: 4.256

3.  25-hydroxyvitamin D, insulin-like growth factor-I, and bone mineral accrual during growth.

Authors:  M E Breen; E M Laing; D B Hall; D B Hausman; R G Taylor; C M Isales; K H Ding; N K Pollock; M W Hamrick; C A Baile; R D Lewis
Journal:  J Clin Endocrinol Metab       Date:  2010-10-20       Impact factor: 5.958

4.  Failure of IGF-I and IGFBP-3 to diagnose growth hormone insufficiency.

Authors:  H Mitchell; M T Dattani; V Nanduri; P C Hindmarsh; M A Preece; C G Brook
Journal:  Arch Dis Child       Date:  1999-05       Impact factor: 3.791

5.  Insulin-like growth factor-1 acts as a zeitgeber on hypothalamic circadian clock gene expression via glycogen synthase kinase-3β signaling.

Authors:  Andreas Breit; Laura Miek; Johann Schredelseker; Mirjam Geibel; Martha Merrow; Thomas Gudermann
Journal:  J Biol Chem       Date:  2018-09-14       Impact factor: 5.157

6.  Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population.

Authors:  G Aimaretti; M Boschetti; G Corneli; V Gasco; D Valle; M Borsotti; A Rossi; A Barreca; L Fazzuoli; D Ferone; E Ghigo; F Minuto
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

7.  The trajectory of IGF-1 across age and duration of type 1 diabetes.

Authors:  Mari Palta; Tamara J LeCaire; Mona Sadek-Badawi; Victor M Herrera; Kirstie K Danielson
Journal:  Diabetes Metab Res Rev       Date:  2014-11       Impact factor: 4.876

8.  Obesity-related markers and breast cancer in CPS-II Nutrition Cohort.

Authors:  Mia M Gaudet; Alpa V Patel; Lauren R Teras; Juzhong Sun; Peter T Campbell; Victoria L Stevens; Eric J Jacobs; Susan M Gapstur
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12

9.  Associations of serum insulin-like growth factor-I and insulin-like growth factor-binding protein 3 levels with biomarker-calibrated protein, dairy product and milk intake in the Women's Health Initiative.

Authors:  Jeannette M Beasley; Marc J Gunter; Andrea Z LaCroix; Ross L Prentice; Marian L Neuhouser; Lesley F Tinker; Mara Z Vitolins; Howard D Strickler
Journal:  Br J Nutr       Date:  2013-10-07       Impact factor: 3.718

10.  Association of insulin-like growth factor-1 with thyroid nodules.

Authors:  Ying-Jian Liu; Wei Qiang; Xing-Jun Liu; Li Xu; Hui Guo; Li-Ping Wu; Bingyin Shi
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.